Todd Nicholson
Payments from drug & device makers
Across 133 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$335
- Novo Nordisk$307
- Lilly USA, LLC$255
- AbbVie$188
- Boehringer Ingelheim$163
- GSK$111
- plus $891 from 23 others
What the payments were for
- Food & beverage$2,250100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $335 |
| Novo Nordisk | 20 | $307 |
| Lilly USA, LLC | 17 | $255 |
| AbbVie | 9 | $188 |
| Boehringer Ingelheim | 11 | $163 |
| GSK | 7 | $111 |
| Phathom Pharmaceuticals, Inc. | 6 | $96 |
| Exact Sciences | 5 | $95 |
| Pfizer | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Merck | 4 | $55 |
| Supernus Pharmaceuticals, Inc. | 1 | $53 |
| Johnson & Johnson | 3 | $41 |
| Bayer | 3 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Abbott | 2 | $38 |
| Amgen | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Tolmar, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Mylan Specialty L.p. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Agepha Pharma FZ LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Novartis | 1 | $14 |
How this compares
$2,250 in reported general payments places this provider in the 75th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $80,404 |
| OzempicSemaglutide | 70 | $72,127 |
| EliquisApixaban | 62 | $69,978 |
| JanuviaSitagliptin Phosphate | 27 | $27,752 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $20,679 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $20,279 |
| TrulicityDulaglutide | 16 | $16,985 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,949 |
| FarxigaDapagliflozin Propanediol | 14 | $11,622 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,491 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $6,473 |
| MyrbetriqMirabegron | 13 | $5,940 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,928 |
| GemtesaVibegron | 11 | $5,368 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $163 | $86,877112 claims |
| Novo NordiskOzempic | $307 | $72,12770 claims |
| PfizerEliquis | $69 | $69,97862 claims |
| MerckJanuvia, Janumet Xr, Dulera | $55 | $37,63050 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $111 | $37,62867 claims |
| AstraZenecaFarxiga, Symbicort | $335 | $18,11340 claims |
| Lilly USA, LLCTrulicity | $255 | $16,98516 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $5,94013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 medical providers in North Carolina.
Other medical in Vass
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$269K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.